Change search criteria ↓

Search results

22 projects found matching your search criteria:

  1. 1. Uracil in DNA and aberrant DNA methylation/hydroxymethylation as a new biomarkers of multiple myeloma development? A sea…

    Principal investigator: prof. Ryszard Oliński

    Uniwersytet Mikołaja Kopernika, Collegium Medicum im. Ludwika Rydygiera w Bydgoszczy, Wydział Farmaceutyczny

    Call: OPUS 20, Panel: NZ5

  2. 2. Evaluation of primary and secondary molecular disorders determinig drug resistance from a group of proteasome inhibitors…

    Principal investigator: prof. Tadeusz Jerzy Robak

    Uniwersytet Medyczny w Łodzi, Wydział Lekarski

    Call: OPUS 12, Panel: NZ5

  3. 3. Prolonged-release of selected antiangiogenic proteins from innovative nanocarrier for use in adjuvant/additive multiple …

    Principal investigator: prof. Bogusław Bronisław Machaliński

    Pomorski Uniwersytet Medyczny w Szczecinie

    Call: OPUS 28, Panel: NZ7

  4. 4. Gankyrin protein as a new potential therapeutic target in multiple myeloma

    Principal investigator: dr hab. Irena Misiewicz-Krzemińska

    Instytut Hematologii i Transfuzjologii

    Call: OPUS 18, Panel: NZ5

  5. 5. The role of PIM kinases in the vascular niche of multiple myeloma

    Principal investigator: Filip Aleksander Garbicz

    Instytut Hematologii i Transfuzjologii

    Call: PRELUDIUM 16, Panel: NZ5

  6. 6. Determining the role of basigin in multiple myeloma and acute myeloid leukaemia development

    Principal investigator: Piotr Stanisław Łacina

    Instytut Immunologii i Terapii Doświadczalnej im. Ludwika Hirszfelda Polskiej Akademii Nauk

    Call: PRELUDIUM 15, Panel: NZ5

  7. 7. Association of TXNDC5 and calreticulin with decreased ER stress, allowing resistant multiple myeloma cells to by-pass pr…

    Principal investigator: Tadeusz Franciszek Kubicki

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Lekarski

    Call: PRELUDIUM 15, Panel: NZ5

  8. 8. Determination of arginase-1 as a potential drug target in the treatment of multiple myeloma and in reducing proteasome i…

    Principal investigator: prof. Jakub Adam Gołąb

    Warszawski Uniwersytet Medyczny, Wydział Lekarski

    Call: OPUS 13, Panel: NZ6

  9. 9. Proteomic analysis of myeloma plasma cells to determine proteins and pathways involved in acquired resistance to proteas…

    Principal investigator: dr Dominik Dytfeld

    Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Lekarski II

    Call: OPUS 13, Panel: NZ5

  10. 10. The role of neurotrophins and angiogenic cytokines in the pathophysiology of treatment-induced peripheral neuropathy in …

    Principal investigator: prof. Bogusław Bronisław Machaliński

    Pomorski Uniwersytet Medyczny w Szczecinie, Wydział Medycyny i Stomatologii

    Call: OPUS 12, Panel: NZ7

  11. 11. Evaluation of anticancer potential of glutamine metabolism modulation in multiple myeloma sensitive and resistant to che…

    Principal investigator: Monika Katarzyna Prełowska

    Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego

    Call: PRELUDIUM 11, Panel: NZ5

  12. 12. Integrity of E3 ubiquitin ligase complex as a biomarker of response to treatment with immunomodulatory drugs in patients…

    Principal investigator: dr hab. Ewa Lech-Marańda

    Instytut Hematologii i Transfuzjologii

    Call: OPUS 7, Panel: NZ5

  13. 13. Characteristics of neuropilin-1 (NRP1) as a target of antiangiogenic activity of immunomodulatory drugs in multiple myel…

    Principal investigator: prof. Krzysztof Giannopoulos

    Uniwersytet Medyczny w Lublinie, II Wydział Lekarski z Oddziałem Anglojęzycznym

    Call: OPUS 7, Panel: NZ6

  14. 14. The influence of hypoxia on functional features of multiple myeloma cells

    Principal investigator: dr Kinga Anna Kocemba

    Uniwersytet Jagielloński- Collegium Medicum, Collegium Medicum; Wydział Lekarski

    Call: PRELUDIUM 5, Panel: NZ1

  15. 15. Role of the human RNA exosome catalytic subunit DIS3 in multiple myeloma pathogenesis and cell physiology.

    Principal investigator: prof. Andrzej Stanisław Dziembowski

    Uniwersytet Warszawski, Wydział Biologii

    Call: MAESTRO 1, Panel: NZ1

  16. 16. The proangiogenic functions of PIM kinases in plasma cell myeloma

    Principal investigator: Filip Aleksander Garbicz

    Instytut Hematologii i Transfuzjologii

    Call: ETIUDA 8, Panel: NZ5

  17. 17. How dysfunction in the nuclear, RNA degrading enzyme DIS3 leads to mitotic defects creating a possible therapeutic strat…

    Principal investigator: dr Tomasz M. Kuliński

    Międzynarodowy Instytut Biologii Molekularnej i Komórkowej

    Call: SONATINA 3, Panel: NZ2

  18. 18. Cognitive functioning of patients with multiple myeloma and biological factors as well as psychosocial variables shaping…

    Principal investigator: Magdalena Bury-Kamińska

    Uniwersytet Marii Curie-Skłodowskiej w Lublinie, Wydział Pedagogiki i Psychologii

    Call: PRELUDIUM 14, Panel: HS6

  19. 19. The role of the gut microbiota in the pathogenesis of plasma cell dyscrasias

    Principal investigator: Marcin Mateusz Jasiński

    Warszawski Uniwersytet Medyczny

    Call: PRELUDIUM 21, Panel: NZ6

  20. 20. The role of Fam46C in B cell phisiology

    Principal investigator: dr Seweryn Mroczek

    Uniwersytet Warszawski, Wydział Biologii

    Call: OPUS 14, Panel: NZ2

  21. 21. Oncogenic mechanisms of DIS3 mutations

    Principal investigator: prof. Andrzej Stanisław Dziembowski

    Instytut Biochemii i Biofizyki PAN

    Call: MAESTRO 8, Panel: NZ4

  22. 22. Analysis of the effect of the DIS3 mutations on the viability, development and tumor formation in mice

    Principal investigator: dr hab. Andrzej Stanisław Dziembowski

    Instytut Biochemii i Biofizyki PAN

    Call: HARMONIA 5, Panel: NZ4

Graphic design and implementation: Jakub Piotrowski